SecBot SecBot
SECBOTREPLAY Home › Report › IRON

IRON · Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the…

Disc Medicine Inc · PRESS-RELEASE filed May 5, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed May 5, 2026 at 08:30 ET

Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the -$1.73 consensus by 4.6%, but net loss widened to $63.5M from $34.1M a year ago on higher R&D and SG&A costs. The key catalyst is the completed enrollment of the Phase 3 APOLLO trial for bitopertin in EPP, with topline data expected in Q4 2026, which could support an FDA resubmission by mid-2027.

  • Q1 2026 EPS of -$1.65 vs consensus -$1.73 (4.6% beat)
  • Net loss widened to $63.5M from $34.1M YoY, driven by higher R&D ($45.9M vs $27.8M) and SG&A ($23.6M vs $12.2M)
  • Cash, cash equivalents, and marketable securities of $730.2M, providing runway into 2029
  • Phase 3 APOLLO trial of bitopertin in EPP fully enrolled (183 patients); topline data expected Q4 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access